BASKING RIDGE, N.J. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding the use of non-invasive vagus nerve stimulation (nVNS) for the acute and preventive treatment of
Extension maintains listing through March 17, 2026 ROCKAWAY, N.J. , Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National
Extension maintains listing through June 3, 2023 ROCKAWAY, N.J. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in the NHS Supply Chain catalogue for an additional two
Basking Ridge, New Jersey: ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016. Desitin,
BASKING RIDGE, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1 . Mr.
Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer BASKING RIDGE, N.J. , March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr.
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Investment to fund commercialization of gammaCore ® and further clinical development of nVNS Basking Ridge, NJ, November 29, 2017 – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
ROCKAWAY, NJ , June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its available tax benefits through the New Jersey Economic Development Authority’s Technology
ROCKAWAY, N.J. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology